TrialsgrambetaRCTs are beautiful

CHEST

2012

Crystalloid versus Hydroxyethyl Starch Trial

In 7,000 ICU patients, 6% HES 130/0.4 did not reduce 90-day mortality versus saline, but increased renal-replacement therapy.

Result

90-day all-cause mortality
Absolute difference
1 points

The absolute difference is derived from the event rates.

Also reported: RRT 7.0% vs 5.8% (p=0.04).

Original publication
Subtopic
Hydroxyethyl starch
Design
Multicentre RCT, ANZ
Relevance
Practice-defining: a trial the field needs to know.
Source
Myburgh JA, et al. N Engl J Med. 2012;367(20):1901-1911.doi 10.1056/NEJMoa1209759

Discussion & critique

With 6S and VISEP, retired HES from ICU resuscitation worldwide.